Brain Cancer Treatment; A Systematic Review

IF 0.4 Q4 ONCOLOGY

International Journal of Cancer Management Pub Date : 2022-07-30 DOI:10.5812/ijcm-121473

Touba Eslaminejad, S. Nematollahi-Mahani, Roghayeh Ershad Sarabi, M. Ohadi, Tahereh Eslaminejad, M. Ansari, Vida Mirzaie

{"title":"Brain Cancer Treatment; A Systematic Review","authors":"Touba Eslaminejad, S. Nematollahi-Mahani, Roghayeh Ershad Sarabi, M. Ohadi, Tahereh Eslaminejad, M. Ansari, Vida Mirzaie","doi":"10.5812/ijcm-121473","DOIUrl":null,"url":null,"abstract":"Context: One of the most common aggressive and primary brain tumors is glioma. The majority of diagnoses are referred to high-grade malignant glioblastoma, which carries the worst prognosis. Still, treatment of brain tumors remains a big challenge for clinicians. This study was designed to investigate the efficacy of gene therapy in the treatment of brain cancer. Methods: Studies use genes as a therapeutic agent in brain cancer treatment even alone or in combination with other treatment methods. Full-text papers, which met the inclusion criteria, were independently assessed by two reviewers. Disagreements were resolved by consultation with a third reviewer. Results: Statistical analysis showed that 50% of the papers used a virus, 36% used polymers, and 14% used cells as carriers to transfect the genes as a therapeutic agent in brain tumor models. Data showed that the estimated size of the brain tumor was reduced by using co-treatment of the gene with one of the conventional therapies. Conclusions: According to the results, co-treatment of the gene with conventional therapies could be more effective than the monotherapy methods.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"113 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2022-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-121473","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Context: One of the most common aggressive and primary brain tumors is glioma. The majority of diagnoses are referred to high-grade malignant glioblastoma, which carries the worst prognosis. Still, treatment of brain tumors remains a big challenge for clinicians. This study was designed to investigate the efficacy of gene therapy in the treatment of brain cancer. Methods: Studies use genes as a therapeutic agent in brain cancer treatment even alone or in combination with other treatment methods. Full-text papers, which met the inclusion criteria, were independently assessed by two reviewers. Disagreements were resolved by consultation with a third reviewer. Results: Statistical analysis showed that 50% of the papers used a virus, 36% used polymers, and 14% used cells as carriers to transfect the genes as a therapeutic agent in brain tumor models. Data showed that the estimated size of the brain tumor was reduced by using co-treatment of the gene with one of the conventional therapies. Conclusions: According to the results, co-treatment of the gene with conventional therapies could be more effective than the monotherapy methods.

查看原文本刊更多论文

脑癌治疗;系统回顾

背景:胶质瘤是最常见的侵袭性原发性脑肿瘤之一。大多数诊断为高度恶性胶质母细胞瘤，其预后最差。尽管如此，脑肿瘤的治疗对临床医生来说仍然是一个巨大的挑战。本研究旨在探讨基因疗法治疗脑癌的疗效。方法:研究将基因作为脑癌治疗的一种治疗剂，甚至单独或与其他治疗方法联合使用。符合纳入标准的全文论文由两位审稿人独立评估。分歧通过与第三位审稿人协商解决。结果:统计分析表明，50%的论文使用病毒，36%使用聚合物，14%使用细胞作为载体转染基因作为脑肿瘤模型的治疗剂。数据显示，通过将该基因与一种常规疗法联合使用，脑肿瘤的估计大小减小了。结论:该基因与常规疗法联合治疗的效果优于单一疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Cancer Management ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.